Cardiff Oncology, Inc. Stock price

Equities

CRDF

US14147L1089

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
5.75 USD +6.68% Intraday chart for Cardiff Oncology, Inc. +15.93% +288.51%
Sales 2024 * 242K Sales 2025 * 66.67K Capitalization 257M
Net income 2024 * -46M Net income 2025 * -57M EV / Sales 2024 * 1,059 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 3,853 x
P/E ratio 2024 *
-5.9 x
P/E ratio 2025 *
-5.46 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.32%
More Fundamentals * Assessed data
Dynamic Chart
1 day+6.68%
1 week+15.93%
Current month+225.78%
1 month+223.03%
3 months+278.29%
6 months+259.38%
Current year+288.51%
More quotes
1 week
5.01
Extreme 5.01
6.42
1 month
1.74
Extreme 1.74
6.42
Current year
1.44
Extreme 1.44
6.42
1 year
0.94
Extreme 0.94
6.42
3 years
0.94
Extreme 0.94
10.24
5 years
0.70
Extreme 0.701
25.50
10 years
0.70
Extreme 0.701
977.76
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 13-03-03
Director of Finance/CFO 53 21-07-11
Chief Tech/Sci/R&D Officer 59 22-01-10
Members of the board TitleAgeSince
Director/Board Member 77 20-04-21
Director/Board Member 76 20-04-21
Chief Executive Officer 64 13-03-03
More insiders
Date Price Change Volume
24-03-27 5.75 +6.68% 1,766,935
24-03-26 5.39 -8.80% 1,449,028
24-03-25 5.91 +1.03% 1,971,677
24-03-22 5.85 +13.81% 2,737,034
24-03-21 5.14 +3.63% 795,514

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies across a range of cancers with unmet medical needs. The Company is focused on tumor vulnerabilities with treatment combinations of onvansertib, its selective PLK1 inhibitor, and standard of care (SoC) therapeutics. The Company has five ongoing clinical trials of onvansertib, including two trials (TROV-054 and ONSEMBLE) in second-line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer (mCRC), one trial in second-line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), and two investigator-initiated trials in patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer (TNBC) and relapsed Small Cell Lung Cancer (SCLC). The Company has third-party manufacturers and distributors to supply and distribute onvansertib used in its clinical studies and nonclinical development programs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.75 USD
Average target price
9.893 USD
Spread / Average Target
+72.06%
Consensus
  1. Stock
  2. Equities
  3. Stock Cardiff Oncology, Inc. - Nasdaq